	US 12,150,970 B2
	Composition for treatment of topical dermatological bacterial skin conditions
Gary Michael Pekoe, Cincinnati, OH (US); Jazmyne Kristyne Mink, Cincinnati, OH (US); Steven Aaron Pentelnik, Cincinnati, OH (US); Neal G. Koller, Annapolis, MD (US); Daniel Banov, Sugar Land, TX (US); and Zahraa I. Foraida, Pearland, TX (US)
Assigned to Alphyn Biologics, Inc., Annapolis, MD (US)
Filed by ALPHYN BIOLOGICS, INC., Annapolis, MD (US)
Filed on Feb. 25, 2022, as Appl. No. 17/680,970.
Claims priority of provisional application 63/189,276, filed on May 17, 2021.
Claims priority of provisional application 63/153,864, filed on Feb. 25, 2021.
Prior Publication US 2022/0265750 A1, Aug. 25, 2022
Int. Cl. A61K 36/47 (2006.01); A61K 45/06 (2006.01); A61P 17/00 (2006.01); A61P 31/04 (2006.01); A61P 31/00 (2006.01)

CPC A61K 36/47 (2013.01) [A61K 45/06 (2013.01); A61P 17/00 (2018.01); A61P 31/04 (2018.01); A61P 31/00 (2018.01)]

56 Claims

1. A hydrogel formulation comprising:

filtered latex of Croton lechleri, glycerin, methylparaben, propylparaben, water, sodium phosphate dibasic heptahydrate, sodium phosphate monobasic, sodium hexametaphosphate, medium chain triglycerides, acrylamide, sodium acryloyldimethyl taurate copolymer, isohexadecane, and polysorbate 80;

wherein the Croton lechleri contains at least about 110 PPM of Gallocatechin, at least about 780 PPM of Epigallocatechin, at least about 1.6 PPM of Catechin, at least about 2 PPM of Epicatechin, at least about 45 PPM Taspine, at least about 0.1 PPM of dimethylcedrusin and wherein the Croton lechleri has a polydispersity index of about 0.5 to about 0.85.